Emerging Frontiers in Biological Sciences for Stem Cell Therapy and Regenerative Medicine
Keywords:
Stem cells, regenerative medicine, tissue engineering, organoids, cellular reprogramming, biomaterials, immunomodulation, translational therapyAbstract
Stem cell therapy and regenerative medicine represent transformative approaches in modern biomedical science. These fields offer innovative potential to repair or replace damaged tissues and organs, leveraging the inherent regenerative capacity of stem cells. The integration of cutting-edge biological sciences—including molecular signaling pathways, biomaterials, and genetic engineering—is driving new paradigms in therapy and clinical application. This paper explores the emerging scientific frontiers shaping the future of stem cell therapy, highlighting interdisciplinary progress in cellular reprogramming, immunomodulation, 3D bioprinting, and organoid technology
References
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676.
Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–147.
Scadden DT. The stem-cell niche as an entity of action. Nature. 2006;441(7097):1075–1079.
Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell. 2006;126(4):677–689.
Griffith LG, Naughton G. Tissue engineering—current challenges and expanding opportunities. Science. 2002;295(5557):1009–1014.
Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell. 2008;132(4):661–680.
Clevers H. Modeling development and disease with organoids. Cell. 2016;165(7):1586–1597.
Zhang YS, Yue K, Aleman J, et al. 3D bioprinting for tissue and organ fabrication. Ann Biomed Eng. 2017;45(1):148–163.
Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–1920.
Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17(1):11–22.
Gilbert PM, Havenstrite KL, Magnusson KE, et al. Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science. 2010;329(5995):1078–1081.
Chen KG, Mallon BS, McKay RD, Robey PG. Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics. Cell Stem Cell. 2014;14(1):13–26.
Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med. 2013;19(8):998–1004.
Huch M, Koo BK. Modeling mouse and human development using organoid cultures. Development. 2015;142(18):3113–3125.
Murphy SV, Atala A. 3D bioprinting of tissues and organs. Nat Biotechnol. 2014;32(8):773–785.
Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet. 2019;20(7):377–388.
Hynes RO. The extracellular matrix: not just pretty fibrils. Science. 2009;326(5957):1216–1219.
Martin I, Wendt D, Heberer M. The role of bioreactors in tissue engineering. Trends Biotechnol. 2004;22(2):80–86.
Yin H, Price F, Rudnicki MA. Satellite cells and the muscle stem cell niche. Physiol Rev. 2013;93(1):23–67.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Sanjana Soham (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
